Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)KVISTGAARD, Denmark - Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The vaccines will be delivered in 2009. The size and value of the contract is undisclosed. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.FREISING-WEIHENSTEPHAN, Germany - Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris’ proprietary Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development with a goal of developing agents for the treatment of serious ocular disorders. 22nd ECNP Congress 2009: The Role of Genetic Factors in Adult ADHDISTANBUL - At the 22nd ECNP Congress, Dr. Barbara Franke, Radboud University Nijmegen Medical Centre, The Netherlands, presented today the latest findings in the identification of ADHD risk genes. “Converging evidence suggests that ADHD aetiology has a robust genetic component”, said Franke. Heritability of adult ADHD appears even higher than that in children: whereas a sibling of a child with ADHD has a 3-4-fold increased risk compared to control children, this risk-increase is 17-fold for a sibling of an adult ADHD patient. Major breakthroughs are expected from the International Multicenter persistent ADHD CollaboraTion (IMpACT), which is investigating the largest clinical ADHD sample worldwide. Early Administration of Aggrenox(R) is Effective and Safe After Acute Ischaemic Stroke or TIAINGELHEIM, Germany - - For Healthcare Media Outside the U.S.A., Canada, and Japan Early secondary prevention with Aggrenox(R) (extended-release dipyridamole [200 mg] plus ASA* [25mg]) is at least as effective and safe as initial treatment with ASA 100 mg alone after an ischaemic stroke or transient ischaemic attack (TIA). Results from the EARLY[1] study, presented for the first time at the 13th Congress of the European Federation of Neurological Societies in Florence on 15 September 2009, showed that while functional outcome at 3 months was similar between the two treatment groups there were numerically fewer recurrent ischaemic events in patients who received Aggrenox(R) from the first day after their ischaemic event compared to those patients who received ASA as initial therapy. Helsinn Partners With Eisai for Gelclair in ItalyLUGANO, Switzerland - The Swiss pharmaceutical group Helsinn and Eisai Italy, subsidiary of the Japanese pharmaceutical company, have signed a licensing agreement for the commercialization of the medical device Gelclair in Italy. 22nd ECNP Congress 2009: The Future of SchizophreniaISTANBUL - At the 22nd Congress of the European College of Neuropsychopharmacology (ECNP), Prof. William Carpenter from the Maryland Psychiatric Research Center, USA, gave today an outlook on a paradigm shift in schizophrenia research, which will have major influence on diagnosis and therapy. “In future schizophrenia research, the focus of therapeutic study will move away from schizophrenia as a disease entity onto specific domains of pathology, promoting the development of targeted drug therapies,” said Carpenter. “This may substantially improve the quality of life for patients in the near future, and prepare the field to address recovery, cure and prevention.” Novant Health Rolls Out MEDai’s Predictive Modeling Solution to Nine Hospitals in Three StatesORLANDO, Florida - - MEDai’s Pinpoint Review Clinical Surveillance System Will Help Novant Hospitals Ensure Patient Safety and Quality, Safeguard Hospital Reimbursement Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage TissueMONTREAL and KIEL, Germany - Working in collaboration with Kiel University, researchers at the Kiel- based Collagen Research Institute (CRI) have demonstrated the stimulating effect of special bioactive collagen peptides (FORTIGEL(R)) in the context of cell experiments. Last weekend the CRI presented its research findings at the congress of the Osteoarthritis Research Society International (OARSI) in Montreal. The investigations of the CRI provide an explanation for the findings of a joint clinical trial carried out by Harvard Medical School and Tufts Medical Center - likewise presented at the congress. With the aid of special imaging (MRI) techniques this clinical trial demonstrated that FORTIGEL(R) stimulated cell metabolism in the knee-joint cartilage and promotes the regeneration of cartilage tissue. Dr M Group Selects Health Robotics’ Technology Over RIVA for all of its I.V. Compounding Centers in South East AsiaBOZEN, Italy - Health Robotics today reported that Dr M Group has selected the CytoCare(TM) and i.v.STATION(TM) Robots to be deployed across all of its I.V. Compounding Centers in Malaysia, Singapore, Indonesia, Vietnam, and India. 22nd ECNP Congress 2009: are the Monoamines Involved in Shaping Conduct Disorders?ISTANBUL, Turkey - New findings on the significance of platelet MAO activity and MAO gene variants with regard to antisocial behaviour have today been presented by Prof. Lars Oreland, University of Uppsala, Sweden, at a press conference during the 22nd ECNP Congress. Prof. Oreland outlined that, based on gene-environment interactions, the brain monoamine systems play a crucial role in shaping personality traits and conduct disorder. The monoamine oxidases (MAOs) genes appear to be the first genes strongly linked with either antisocial behaviour or conduct disorder. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San FranciscoPARIS - Novexel, a specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its pipeline will be the subject of 16 posters and one slide presentation at the 49th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The ICAAC meeting, which is taking place in San Francisco, California, September 12-15 2009, is the leading global conference on anti-microbial agents globally with over 10,000 participants. Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer PainLISBON, Portugal - - Head to Head Study Confirms Superiority of the New Intranasal Treatment for Breakthrough Cancer Pain Over OTFC ThromboGenics is Shortlisted for “Biotech Company of the Year” and “Licensing Deal of the Year” at Scrip Awards 2009LEUVEN, Belgium - - ThromboGenics’ Significant Achievements Over the Last Year are Recognised in Nominations Results From Improve Study Show MRI Benefits of Rebif(R) Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over TimeGENEVA - - Data Presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) Held in Dusseldorf, Germany, From September 9-12, 2009. arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to WorkROTTERDAM, The Netherlands - arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful first closing of its Series A equity financing round. The Company raised EUR 9.5million (~ USD 13.6 million) from a syndicate of leading life science investors. The financing round is one of the largest of its kind in the last 12 months. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio StrategyOXFORD, England - PharmaVentures announced today the appointment of Nikki Watkins as Head of the Product & Portfolio Strategy Practice of Corporate Advisory, leading a team of Senior Advisors and Analysts. Elsevier Joins InChI Trust as a Charter MemberNEUCHATEL, Switzerland - Elsevier, a leading publisher of scientific, technical and medical information products and services, today announced it has become one of the Charter Members of the InChI Trust and will have a seat on the board at the first InChI Trust Board meeting on September 11th. Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing CompaniesSTOCKHOLM - Pergamum AB has announced its formation; Pergamum will commercialize the Karolinska Development dermatology and wound healing interests, and create a broad-based therapeutic company in its focus areas. Helix BioPharma Closes Private PlacementAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: “HBP”; OTCQX: “HXBPF”) today announced that it has closed its previously announced private placement of 6,625,000 units at US$2.05 per unit. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics SectionBRIDGEWATER, England - Clinical Therapeutics,( www.clinicaltherapeutics.com/) the world’s premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board. Relaunched Healthcare Republic Provides the Best Online Resources for Primary Care PractitionersLONDON - Users of leading primary care website Healthcare Republic ( www.healthcarerepublic.com/) will now find it easier than ever to find drug and research updates, archived articles and breaking news from all of Haymarket’s medical publications. Tata Interactive Systems Initiates Vertical-Focused Learning Solutions for Health Care, Pharmaceutical, and BiotechnologyMUMBAI, India - - Tata Interactive Systems Announces its First Domain-Specific Learning and Consulting Solutions for Health Care MitraClip(R) Therapy Introduced in AustriaMENLO PARK, California - - Use of the MitraClip(R) System Continues to Expand in Europe /C O R R E C T I O N — Clinical Therapeutics/BRIDGEWATER, New Jersey - In the news release, “Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section” issued on 9 Sep 2009 08:30 GMT, by Clinical Therapeutics over PR Newswire, we are advised by a representative of the company that the Dateline has been changed from “Bridgewater, England” to “Bridgewater, New Jersey” and the contact number has been changed from +44(0)908-547-2094 to +1-908-547-2094 which were incorrectly transmitted by PR Newswire. Complete, corrected release follows: LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus ChallengeBOZEMAN, Montana - LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte’s investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo. Clinical studies to date have shown the vaccine to be immunogenic and generally well tolerated in human subjects. Update on Velaglucerase AlfaCAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is committed to doing everything possible to assist Gaucher patients and their physicians during the imiglucerase supply shortage. Shire is pleased to be able to provide velaglucerase alfa well over a year ahead of previously anticipated commercial launch world wide. Cell Biosciences Signs Agreement to Acquire Alpha InnotechSANTA CLARA, California - Cell Biosciences, Inc. and Alpha Innotech Corp. (OTC Bulletin Board: APNO) today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for US$1.50 per share or approximately US$17.9 million in cash. This acquisition would significantly expand Cell Biosciences’ protein analysis business to include a global infrastructure and a broad protein analysis product portfolio. Tosho’s Satisfaction With Health Robotics Steers the Japanese Pharmacy Automation Leader to Renew and to Expand its I.V. Automation Strategic PartnershipBOZEN, Sud-Tyrol, Italy - Health Robotics today announced that after a successful first year of cooperation in Japan with Tosho Inc., the companies signed this week a contract renewal of the CytoCare(TM) and i.v.STATION(TM) exclusive distribution agreements, and an expansion of their strategic relationship to include future joint-development projects in their respective areas of Pharmacy Automation expertise. Helix BioPharma Announces CDN$13.5 Million Private PlacementAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at CDN$2.05 per unit, for gross proceeds totaling CDN$13,581,250. The Company anticipates closing the private placement by September 11, 2009. Karolinska Development Portfolio Company Completes Successful Phase II Clinical TrialSTOCKHOLM - Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development’s business strategy. A Fifth of People With MDS (Blood Cancer) Die Prematurely Because the NHS Won’t Fund New Life-extending DrugsLONDON - - More Than Half of Blood Cancer Experts (56 Percent) say Less Priority is Given to Rarer Cancers Compared to Other Common Cancers B-R-A-H-M-S and Thermo Fisher Scientific Join Forces to Create a Leader in Specialty DiagnosticsHENNIGSDORF, Germany - B-R-A-H-M-S, a leading diagnostics company, and Thermo Fisher Scientific, the world leader in serving science, join forces to establish a European Center of Excellence for clinical diagnostics with a focus on innovative biomarkers. Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization of Alpharadin for Bone MetastasesOSLO - - Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17PHILADELPHIA - - INTUNIV, the First Nonscheduled alpha-2A receptor agonist indicated for ADHD, Demonstrated Improvement in a Range of ADHD Symptoms That can be Disruptive, Such as Inattention, Arguing With Adults, Hyperactivity, Impulsivity, and Losing One’s Temper CryoLife’s Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the WorldATLANTA - - The Ross Summit 2009 to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft(R) processed human heart valves in the Ross Procedure |
